Oncoinvent presents first half 2026 results
Presentation:
Oncoinvent’s management will give an online presentation to investors, analysts and the press at 10:00am CEST today. It will be possible to submit questions during the presentation.
- Presenters: CEO Oystein Soug, CFO Ramzi Amri
- Time: 10:00am CEST
- Webcast link: https://qcnl.tv/p/FlGvKEVec2WWcnTYYHBK4g
A recording of the webcast will be made available on www.oncoinvent.com after the live sending.
Highlights:
- Achieved 50% recruitment milestone in Phase 2 ovarian cancer study of Radspherin®
- Added four new clinical sites to Oncoinvent’s Phase 2 trial
- Presented positive 24-month follow-up data from Phase 1 ovarian cancer trial of Radspherin® at 27th Congress of the European Society of Gynaecological Oncology (ESGO) 2026
- Appointed Dr Ramzi Amri as Chief Financial Officer (CFO)
- Secured new patent expanding protection for Radspherin®
Post-period highlights:
- Announced publication of normal tissue dosimetry results in Journal of Nuclear Medicine
- Announced abstracts accepted at two major scientific conferences:
- European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (23-27 October)
- European Association of Nuclear Medicine (EANM) Annual Congress 2026 in Vienna, Austria (17-21 October)
Oystein Soug, CEO, commented: “We entered the year with a clear focus on accelerating patient recruitment, and I am pleased to say that these efforts are delivering tangible results. Recruitment momentum accelerated significantly during the first half of the year, reinforcing our confidence in the potential of Radspherin® to address a significant unmet medical need in ovarian cancer.”
Key financial figures
| AMOUNTS IN 1 000 NOK | 1H 2026 | 1H 2025 | FY2025 | |
| Total operating revenue | 8 203 | 11 960 | 28 069 | |
| Total operating expenses | (77 195) | (63 978) | (186 399) | |
| Operating profit (-loss) | (68 992) | (52 018) | (158 330) | |
| Cash | 108 839 | 77 412 | 179 670 | |
| Earnings per share (EPS) | (15.20) | (54.01) | (125.13) | |
| # Shares | 4 478 412 | 962 544 | 1 239 249 | |
| Employees (FTEs) | 42 | 36 | 44 |
The interim financial information has not been subject to audit
Reporting material:
The reporting material are also available in the Investor Relations section of the Company's website at www.oncoinvent.com.
Oncoinvent reports its financial results on a half-yearly basis, complemented by quarterly business updates to keep stakeholders informed and ensure ongoing transparency.